

FOR IMMEDIATE RELEASE

April 2005

David Karlman
Chairman and Chief Executive Officer
American BioHealth Group, LLC
15721 Bernardo Heights Parkway Suite 151
San Diego, California 92128
(ph) 858-675-3600
(fax) 858-613-0748
dkarlman@abgpharma.com
www.thehearingpill.com

**Naval Medical Center San Diego, and American BioHealth Group Announce
Clinical Results on Compound That Protects Against Hearing Loss**

SAN DIEGO, California: The Naval Medical Center San Diego and American BioHealth Group announced today a medical breakthrough that protects against hearing loss. The results of an extensive double blinded, placebo controlled, 566 patient clinical trial confirmed that a novel compound, protected by a patent issued to the United States Navy and licensed exclusively by American BioHealth Group, is effective in preventing hearing loss from noise exposure.

The clinical trial found that permanent hearing loss was reduced in the ear closest to the acoustic trauma when compared to the placebo. The results of this study add to the extensive body of positive evidence done in the laboratory. The complete study detail will be published in several peer-reviewed publications in the coming months.

This study was carried out under the direction of Navy Commander Ben Balough MD. Commander Balough states, "The successful completion of this clinical trial marks an important milestone in the development of a much needed medical solution to prevent hearing loss. Further work will need to be done to refine optimal dosing to achieve maximum benefit. This study substantiates that the effects seen in the laboratory may be translated effectively in humans. The collaboration between Naval Medical Center San Diego and American BioHealth Group is a terrific example of diverse entities joining together for the good of all those individuals who will benefit from this work including, most urgently, our service personnel in all branches of the military."

American BioHealth Group holds the exclusive license to commercialize this compound, and others, that address hearing disorders. The license was initiated and facilitated by the TechLink center, a Bozeman, Mont.-based technology transfer organization, which is funded primarily by the U.S. Department of Defense to move technology to the marketplace.

David Karlman, Chairman and Chief Executive Officer of American BioHealth Group comments "For the first time millions of individuals have available a safe and clinically proven compound that helps prevent the debilitating damaging effects of common noise exposures. This product is available now at www.thehearingpill.com. Additionally, we have anecdotal evidence that this product has some positive effect on tinnitus and balance disorders. We are launching clinical studies to further study these areas.

Further, based on the positive results as evidenced in this clinical trial, we are accelerating our other product development plans and adding new compounds into our growing product pipeline. We will continue to work closely with a number of our valuable partners, domestically and internationally, with the objective of advancing development of other drugs and indications that address hearing disorders."